Summit Therapeutics SMMT Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Summit Therapeutics's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash?
- Summit Therapeutics (SMMT) reported effect of currency exchange rate changes on cash, cash equivalents, and restricted cash of -$19K in Q1 2026.
- How has Summit Therapeutics's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash changed year-over-year?
- Summit Therapeutics's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash decreased by 150.0% year-over-year, from $38K to -$19K.